Cargando...

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of potential use in patients with breast cancer. Unfortunately, in clinical studies, gefitinib is often ineffective indicating that resistance to EGFR inhibitors may be a common occurrence in cancer of the breast...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Giordano, Courtney R., Mueller, Kelly L., Terlecky, Laura J., Krentz, Kendra A., Bollig-Fischer, Aliccia, Terlecky, Stanley R., Boerner, Julie L.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858180/
https://ncbi.nlm.nih.gov/pubmed/22687878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexcr.2012.06.001
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!